The Structural Genomics Consortium (SGC)

🎙️ The Target 2035 podcast series is officially LIVE! In our pilot episode, meet the three hosts - Rachel Harding, Opher Gileadi, and Milka Kostic, Ph.D. - who share their personal motivations for joining the Target 2035 initiative. They dive into the goals of Target 2035, emphasizing the power of open science and community collaboration in advancing drug discovery. This season will bring you engaging conversations with scientists, researchers, and industry experts, exploring new technologies, groundbreaking projects, and inspiring success stories. And guess what? A very special guest will be featured in the next episode, dropping soon! Tune in to the pilot episode now! https://lnkd.in/ep5E5MN2 🎧 Special thanks to Sofia Melliou and Kristina Edfeldt for content creation and episode production and Roxanne Case for editing. #Target2035 #PodcastLaunch #OpenScience #DrugDiscovery #CommunityCollaboration

The 2024 Nobel Prizes were announced last week, with two catching our attention by highlighting the power of machine learning and protein structure prediction. These are core areas of SGC’s work for over 20 years. SGC has been a central figure in open data and collaborative research, contributing more human protein structures to the RCSB Protein Data Bank than any other organization. As Aled Edwards points out, this is the perfect time to be at the crossroads of open data, protein science, and machine learning. Read the full news story: https://lnkd.in/gskhgF-Z

🎙️ Get ready... Something BIG is coming from Target 2035! What if the future of drug discovery could be unlocked by listening in? 👀 Rachel Harding, Milka Kostic, Ph.D. and Opher Gileadi got something brewing, and trust us-you won’t want to miss it. Can you crack the code before it drops? Stay tuned for more… 🎧 #Target2035, #OpenScience, #ComingSoon

New insights into overcoming drug resistance in paclitaxel-resistant triple-negative breast cancer. The researchers used a promising strategy for improved clinical outcomes in the treatment of this subtype of breast cancer. By utilizing an epigenetic chemical probe screen, they uncovered an acquired vulnerability of paclitaxel-resistant TNBC cells to protein arginine methyltransferases inhibition. Read more: https://lnkd.in/e2WwrwjP

A new commentary by Andreas Kraemer and Stefan Knapp is now online. The SGC researchers are highlighting a study, that reveals the potential for therapeutic targeting of the WDR domain of DCAF5 to effectively reverse the malignant state of some aggressive childhood cancers that are driven by disruption of tumor suppressor complexes. Read more: https://lnkd.in/eamvhSEE

Reactome has spotlighted the recent publication of Matthieu Schapira's group! If you haven't already, take a look at how the researchers have determined the chemical coverage of human biological pathways to outline potential approaches in guiding Target 2035 efforts. Check it out: https://lnkd.in/gN76hReV

Today the entire #OpenScience community is celebrating! Congratulations to The Nobel Prize winners in Chemistry, Demis Hassabis, John Jumper and David Baker! Did you know that they had all participated in John Moult's CASP challenges? https://lnkd.in/dAayieCf #NobelPrizeChemistry #DeepMind #AlphaFold #ProteinStuctures

A new model system to functionally test the role of CK1 variants in the Wnt/β-catenin pathway. This experimental system has revealed how CK1α regulates this crucial pathway and provides a foundation for future research into molecular and cellular functions of CK1α and CK1α-like. Read more: https://lnkd.in/eR8mzp6N

An exciting avenue for therapeutic intervention for #HuntingtonsDisease: Researchers have found that the mutated protein in Huntington’s Disease patients fails to repair DNA as intended, affecting the brain cells' ability to self-heal. Read more: https://lnkd.in/gPCDw9Ga

With activities such as its open innovation portal #opnMe and its participation at the Structural Genomics Consortium (SGC), Boehringer Ingelheim is an enthusiastic supporter of #OpenScience initiatives. The SGC through its donated chemical probes initiative, enables pharmaceutical companies and leading academic laboratories to make their innovative high-quality tool compounds freely available to the research community. Watch Susanne Muller-Knapp, COO of SGC Frankfurt, as she speaks about the SGC's partnership with opnMe, and the opportunities this creates for basic research. Learn more on opnMe: https://lnkd.in/eCb8SxND